Artificial Pancreas Project at Cambridge 2013

Diabetic Medicine

Volumn 32, Issue 8, 2015, Pages 987-992

  Hovorka, R ^a,b  

^a INSTITUTE OF METABOLIC SCIENCE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GLUCOSE; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; PRAMLINTIDE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

ARTIFICIAL PANCREAS; BLOOD GLUCOSE MONITORING; DRUG ABSORPTION; DRUG SAFETY; GLUCOSE ABSORPTION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INSULIN TREATMENT; INTESTINE ABSORPTION; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY OF LIFE; REVIEW; ALGORITHM; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; INSULIN INFUSION; METABOLISM;

ALGORITHMS; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS; PANCREAS, ARTIFICIAL;

EID: 84948412726     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12766     Document Type: Review

References (33)

1. Hovorka R. Closed-loop insulin delivery: from bench to clinical practice. Nat Rev Endocrinol 2011; 7: 385-395.
2. Bakhtiani PA, Zhao LM, El YJ, Castle JR, Ward WK. A review of artificial pancreas technologies with an emphasis on bi-hormonal therapy. Diabetes Obes Metab 2013; 15: 1065-1070.
3. Peyser T, Dassau E, Breton M, Skyler JS. The artificial pancreas: current status and future prospects in the management of diabetes. Ann NY Acad Sci 2014; 1311: 102-123.
4. Hovorka R, Allen JM, Elleri D, Chassin LJ, Harris J, Xing D et al. Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial. Lancet 2010; 375: 743-751.
5. Hovorka R, Kumareswaran K, Harris J, Allen JM, Elleri D, Xing D et al. Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies. Br Med J 2011; 342: d1855.
6. Elleri D, Allen JM, Tauschmann M, El-Khairi R, Benitez-Aguirre P, Acerini CL et al. Feasibility of overnight closed-loop therapy in young children with type 1 diabetes aged 3-6 years: comparison between diluted and standard insulin strength. BMJ Open Diabetes Res Care 2014; 2: e000040.
7. Elleri D, Maltoni G, Allen JM, Nodale M, Kumareswaran K, Leelarathna L et al. Safety of closed-loop therapy during reduction or omission of meal boluses in adolescents with type 1 diabetes: a randomized clinical trial. Diabetes Obes Metab 2014; 16: 1174-1178.
8. Luijf YM, DeVries JH, Zwinderman K, Leelarathna L, Nodale M, Caldwell K et al. Day and night closed-loop control in adults with type 1 diabetes: a comparison of two closed-loop algorithms driving continuous subcutaneous insulin infusion versus patient self-management. Diabetes Care 2013; 36: 3882-3887.
9. Murphy HR, Elleri D, Allen JM, Harris J, Simmons D, Rayman G et al. Closed-loop insulin delivery during pregnancy complicated by type 1 diabetes. Diabetes Care 2011; 34: 406-411.
10. Murphy HR, Kumareswaran K, Elleri D, Allen JM, Caldwell K, Biagioni M et al. Safety and efficacy of 24-h closed-loop insulin delivery in well-controlled pregnant women with type 1 diabetes: a randomized crossover case series. Diabetes Care 2011; 34: 2527-2529.
11. Hovorka R, Elleri D, Thabit H, Allen JM, Leelarathna L, El-Khairi R et al. Overnight closed-loop insulin delivery in young people with type 1 diabetes: a free-living, randomized clinical trial. Diabetes Care 2014; 37: 1204-1211.
12. Thabit H, Lubina-Solomon A, Stadler M, Leelarathna L, Walkinshaw E, Pernet A et al. Home use of closed-loop insulin delivery for overnight glucose control in adults with type 1 diabetes: a 4-week, multicentre, randomised crossover study. Lancet Diabetes Endocrinol 2014; 2: 701-709.
13. Thabit H, Elleri D, Leelarathna L, Allen JM, Lubina-Solomon A, Stadler M et al. Unsupervised home use of overnight closed-loop system over 3 to 4 weeks - pooled analysis of randomized controlled studies in adults and adolescents with type 1 diabetes. Diabetes Obes Metab 2015; 17: 452-458.
14. Leelarathna L, Dellweg S, Mader JK, Allen JM, Benesch C, Doll W et al. Day and night home closed-loop insulin delivery in adults with type 1 diabetes: three-center randomized crossover study. Diabetes Care 2014; 37: 1931-1937.
15. Elleri D, Acerini CL, Allen JM, Hayes J, Pesterfield C, Wilinska ME et al. Parental attitudes towards overnight closed-loop glucose control in children with type 1 diabetes. Diabetes Technol Ther 2010; 12: 35-39.
16. Barnard KD, Wysocki T, Allen JM, Elleri D, Thabit H, Leelarathna L et al. Closing the loop overnight at home setting: psychosocial impact for adolescents with type 1 diabetes and their parents. BMJ Open Diabetes Res Care 2014; 2: e000025.
17. Barnard KD, Wysocki T, Thabit H, Evans ML, Amiel SA, Heller SR et al. Psychosocial aspects of closed and open loop adult study: closing the loop in adults with Type 1 diabetes in the home setting. Diabet Med 2015; 32: 601-608.
18. Haidar A, Elleri D, Kumareswaran K, Leelarathna L, Allen JM, Caldwell K et al. Pharmacokinetics of insulin aspart in pump-treated subjects with type 1 diabetes: reproducibility and effect of age, weight, and duration of diabetes. Diabetes Care 2013; 36: e173-e174.
19. Goudie RJ, Lunn D, Hovorka R, Murphy HR. Pharmacokinetics of insulin aspart in pregnant women with type 1 diabetes: every day is different. Diabetes Care 2014; 37: e121-e122.
20. Ruan Y, Elleri D, Allen JM, Tauschmann M, Wilinska ME, Dunger DB et al. Pharmacokinetics of diluted (U20) insulin aspart compared with standard (U100) in children aged 3-6 years with type 1 diabetes during closed-loop insulin delivery: a randomised clinical trial. Diabetologia 2015; 58: 687-690.
21. Elleri D, Allen JM, Harris J, Kumareswaran K, Nodale M, Leelarathna L et al. Absorption patterns of meals containing complex carbohydrates in type 1 diabetes. Diabetologia 2013; 56: 1108-1117.
22. Murphy HR, Elleri D, Allen JM, Harris J, Simmons D, Rayman G et al. Pathophysiology of postprandial hyperglycaemia in women with type 1 diabetes during pregnancy. Diabetologia 2012; 55: 282-293.
23. Leelarathna L, English SW, Thabit H, Caldwell K, Allen JM, Kumareswaran K et al. Feasibility of fully automated closed-loop glucose control utilizing continuous subcutaneous glucose measurements in critical illness: a randomised controlled trial. Crit Care 2013; 17: R159.
24. Leelarathna L, English SW, Thabit H, Caldwell K, Allen JM, Kumareswaran K et al. Accuracy of subcutaneous continuous glucose monitoring in critically ill adults: improved sensor performance with enhanced calibrations. Diabetes Technol Ther 2014; 16: 97-101.
25. Kumareswaran K, Thabit H, Leelarathna L, Caldwell K, Elleri D, Allen JM et al. Feasibility of closed-loop insulin delivery in type 2 diabetes: a randomized controlled study. Diabetes Care 2014; 37: 1198-1203.
26. Bergenstal RM, Klonoff DC, Garg SK, Bode BW, Meredith M, Slover RH et al. Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med 2013; 369: 224-232.
27. Phillip M, Battelino T, Atlas E, Kordonouri O, Bratina N, Miller S et al. Nocturnal glucose control with an artificial pancreas at a diabetes camp. N Engl J Med 2013; 368: 824-833.
28. Del Favero S, Bruttomesso D, Di PF, Lanzola G, Visentin R, Filippi A et al. First use of model predictive control in outpatient wearable artificial pancreas. Diabetes Care 2014; 37: 1212-1215.
29. Nimri R, Muller I, Atlas E, Miller S, Fogel A, Bratina N et al. MD-Logic overnight control for 6 weeks of home use in patients with type 1 diabetes: randomized crossover trial. Diabetes Care 2014; 37: 3025-3032.
30. Russell SJ, El-Khatib FH, Sinha M, Magyar KL, McKeon K, Goergen LG et al. Outpatient glycemic control with a bionic pancreas in type 1 diabetes. N Engl J Med 2014; 371: 313-325.
31. Haidar A, Legault L, Messier V, Mitre TM, Leroux C, Rabasa-Lhoret R. Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial. Lancet Diabetes Endocrinol 2015; 3: 17-26.
32. Weinzimer SA, Sherr JL, Cengiz E, Kim G, Ruiz JL, Carria L et al. Effect of pramlintide on prandial glycemic excursions during closed-loop control in adolescents and young adults with type 1 diabetes. Diabetes Care 2012; 35: 1994-1999.
33. Renukuntla VS, Ramchandani N, Trast J, Cantwell M, Heptulla RA. Role of glucagon-like peptide-1 analogue versus amylin as an adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm. J Diabetes Sci Technol 2014; 8: 1011-1017.